Cargando…

Discordant Biological and Toxicological Species Responses to TLR3 Activation

Toll-like receptors (TLRs) are highly conserved type 1 membrane proteins that initiate a multiplicity of transient gene transcriptions, resulting in innate and adaptive immune responses. These essential immune responses are triggered by common TLR pattern recognition receptors of microbial products...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, William M., Nicodemus, Christopher F., Carter, William A., Horvath, Joseph C., Strayer, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Investigative Pathology. Published by Elsevier Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093871/
https://www.ncbi.nlm.nih.gov/pubmed/24486326
http://dx.doi.org/10.1016/j.ajpath.2013.12.006
_version_ 1783510365083009024
author Mitchell, William M.
Nicodemus, Christopher F.
Carter, William A.
Horvath, Joseph C.
Strayer, David R.
author_facet Mitchell, William M.
Nicodemus, Christopher F.
Carter, William A.
Horvath, Joseph C.
Strayer, David R.
author_sort Mitchell, William M.
collection PubMed
description Toll-like receptors (TLRs) are highly conserved type 1 membrane proteins that initiate a multiplicity of transient gene transcriptions, resulting in innate and adaptive immune responses. These essential immune responses are triggered by common TLR pattern recognition receptors of microbial products expressed through the cytoplasmic carboxy-terminal Toll/IL-1 domain. Toll/IL-1 adapter protein cascades are induced by an activated Toll/IL-1 to induce transient transcription responses. All TLRs, with the exception of TLR3, use an MyD88 adapter to Toll/IL-1 to initiate a proinflammatory cascade. TLR3 uses the toll receptor 3/4 induction factor adapter to initiate a different cytosolic adapter cascade with double-stranded RNA agonists. This non-MyD88 pathway induces both NF-κB and type 1 interferon responses. By using a TLR3-restricted double-stranded RNA agonist, rintatolimod, we demonstrate significant unexpected differences in toxic responses between rats and primates. The mechanism of this differential response is consistent with a relative down-regulation of the NF-κB inflammatory cytokine induction pathway in the cynomolgus monkey and humans, but not observed systemically in rat. Our findings suggest evaluation of TLR3 agonists in drug therapy.
format Online
Article
Text
id pubmed-7093871
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Society for Investigative Pathology. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-70938712020-03-25 Discordant Biological and Toxicological Species Responses to TLR3 Activation Mitchell, William M. Nicodemus, Christopher F. Carter, William A. Horvath, Joseph C. Strayer, David R. Am J Pathol Article Toll-like receptors (TLRs) are highly conserved type 1 membrane proteins that initiate a multiplicity of transient gene transcriptions, resulting in innate and adaptive immune responses. These essential immune responses are triggered by common TLR pattern recognition receptors of microbial products expressed through the cytoplasmic carboxy-terminal Toll/IL-1 domain. Toll/IL-1 adapter protein cascades are induced by an activated Toll/IL-1 to induce transient transcription responses. All TLRs, with the exception of TLR3, use an MyD88 adapter to Toll/IL-1 to initiate a proinflammatory cascade. TLR3 uses the toll receptor 3/4 induction factor adapter to initiate a different cytosolic adapter cascade with double-stranded RNA agonists. This non-MyD88 pathway induces both NF-κB and type 1 interferon responses. By using a TLR3-restricted double-stranded RNA agonist, rintatolimod, we demonstrate significant unexpected differences in toxic responses between rats and primates. The mechanism of this differential response is consistent with a relative down-regulation of the NF-κB inflammatory cytokine induction pathway in the cynomolgus monkey and humans, but not observed systemically in rat. Our findings suggest evaluation of TLR3 agonists in drug therapy. American Society for Investigative Pathology. Published by Elsevier Inc. 2014-04 2014-01-30 /pmc/articles/PMC7093871/ /pubmed/24486326 http://dx.doi.org/10.1016/j.ajpath.2013.12.006 Text en Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mitchell, William M.
Nicodemus, Christopher F.
Carter, William A.
Horvath, Joseph C.
Strayer, David R.
Discordant Biological and Toxicological Species Responses to TLR3 Activation
title Discordant Biological and Toxicological Species Responses to TLR3 Activation
title_full Discordant Biological and Toxicological Species Responses to TLR3 Activation
title_fullStr Discordant Biological and Toxicological Species Responses to TLR3 Activation
title_full_unstemmed Discordant Biological and Toxicological Species Responses to TLR3 Activation
title_short Discordant Biological and Toxicological Species Responses to TLR3 Activation
title_sort discordant biological and toxicological species responses to tlr3 activation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093871/
https://www.ncbi.nlm.nih.gov/pubmed/24486326
http://dx.doi.org/10.1016/j.ajpath.2013.12.006
work_keys_str_mv AT mitchellwilliamm discordantbiologicalandtoxicologicalspeciesresponsestotlr3activation
AT nicodemuschristopherf discordantbiologicalandtoxicologicalspeciesresponsestotlr3activation
AT carterwilliama discordantbiologicalandtoxicologicalspeciesresponsestotlr3activation
AT horvathjosephc discordantbiologicalandtoxicologicalspeciesresponsestotlr3activation
AT strayerdavidr discordantbiologicalandtoxicologicalspeciesresponsestotlr3activation